NCT06809400
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
At risk: Primary completion moved at least 8 months later, enrollment reduced 29%.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 16 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Jan 2028 to Oct 2028
- Eligibility criteria expanded, about 34 words
- Enrollment reduced: 127 → 90 participants
- Study description expanded, about 2 words
- Minor Site details revised at 10 of 14 sitesv17
- Notable Eligibility criteria expanded, about 50 words
- Site contacts updated at 1 of 14 sites
- Minor Site details revised at 1 of 14 sitesv15
- Minor Study sites: 13 to 14v13
Show 10 earlier versionsHide 10 earlier versions
- Minor Site details revised at 1 of 13 sitesv12
- Minor Site contacts updated at 1 of 13 sitesv11
- Minor Study sites: 14 to 13v10
- Minor Study sites: 13 to 14v9
- Notable Eligibility criteria expanded, about 36 wordsv8
- Minor Secondary endpoints: 4 to 6v7
- Minor Site contacts updated at 1 of 13 sitesv6
Notable Eligibility criteria revisedv5 Show 4 more changesShow less
- Primary endpoints revised (4)
- Primary and study completion dates: Nov 2027 to Jan 2028
- Secondary endpoints revised (4)
- Study sites revised (13)
- Minor Study sites: 2 to 13v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: May 2028 to Nov 2027
- Start date changed from estimate of Feb 2025 to Feb 18, 2025
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A
Timeframe: Baseline to Week 48
Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A
Timeframe: Baseline to Week 48
Number of Participants with One or More SAEs Part B
Timeframe: Baseline to Week 61
Number of Participants with One or More TEAEs Part B
Timeframe: Baseline to Week 61
Secondary (6)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 ARC-Associated Antisense Part A
PK: Cmax of LY4006896 ARC-Associated Antisense Part B
PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 ARC-Associated Antisense Part A
PK: AUC of LY4006896 ARC-Associated Antisense Part B
Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Skin Part B
Show 1 moreShow less
Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Cerebrospinal Fluid (CSF) Part B
Arms and interventions
Part A LY4006896 + PlaceboExperimental
Healthy participants will receive a single escalating dose of LY4006896 and matching placebo.
Part B LY4006896 + PlaceboExperimental
Participants with Parkinson's disease will receive multiple doses of LY4006896 and matching placebo.
Drugs: LY4006896, Placebo
Sites
14 sites in 2 countries
United States 12, Japan 2